TOKYO -- Japanese drugmaker Eisai will apply for regulatory approval in the U.S. for preventative use of its Alzheimer's drug lecanemab as soon as the fiscal year starting April 2026.
Lecanemab, if it proves safe and effective, would enable prevention of the disease in its early stages, potentially reducing medical and nursing care costs. Preventative use of lecanemab, which goes by the brand name Leqembi, is designed for patients who have accumulated amyloid beta, a protein believed to cause Alzheimer's disease, in their brains but have not yet developed symptoms of dementia.
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
